Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
Public ClinicalTrials.gov record NCT00439244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis
Study identification
- NCT ID
- NCT00439244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis
- Industry
- Enrollment
- 412 participants
Conditions and interventions
Conditions
Interventions
- Zoledronic acid Drug
- Placebo Drug
- Teriparatide Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years to 89 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2006
- Primary completion
- Jan 31, 2009
- Completion
- Jan 31, 2009
- Last update posted
- Apr 19, 2011
2006 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | La Mesa | California | — | — |
| Novartis Investigative Site | Oakland | California | — | — |
| Not listed | Colorado Springs | Colorado | 80910 | — |
| Not listed | Lakewood | Colorado | 80227 | — |
| Not listed | Gainesville | Georgia | 30501 | — |
| Not listed | Morton Grove | Illinois | 60053 | — |
| Not listed | Urbandale | Iowa | 50322 | — |
| Not listed | Bangor | Maine | 04401 | — |
| Novartis Investigative Site | Woodbury | Minnesota | — | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Lincoln | Nebraska | 68516 | — |
| Not listed | Albuquerque | New Mexico | 87106 | — |
| Not listed | West Haverstraw | New York | 10993 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15253 | — |
| Novartis Investigative Site | Spokane | Washington | — | — |
| Not listed | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00439244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00439244 live on ClinicalTrials.gov.